step for the evaluation of ischemic heart disease in women. 7 Several methods are now available and have been established for measuring CFR. However, these methods are either invasive or costly and, consequently, rarely obtainable. 8, 9 Noninvasive assessment of coronary flow velocity reserve (CFVR) with transthoracic echocardiography (TTE) has been proposed in the past as a method for assessing CFR by measuring blood flow velocity before and after pharmacologicalinduced vasodilation, 10 and is now being used more and more often as a method to evaluate the effects of epicardial coronary stenosis [10] [11] [12] and coronary microvasculature function. [13] [14] [15] [16] [17] Thus, the purpose of this study was to evaluate the safety and to analyze the feasibility, the adverse event profile and complication rate of noninvasive CFVR study assessed with TTE in women with known or suspected CAD over a period of 10 years in a single clinical cardiology center.
| METHODS

| Study group
From January 2000 to December 2010, we performed 1455 CFVR studies in women referred to our stress echo laboratory for known and suspected CAD.
None of the patients had a history of asthma or advanced atrioventricular block or sick sinus syndrome not controlled by pacemaker.
The patients (age 66.4±11.9 years) were referred for CFVR studies for different reasons: planned follow-up after elective and primary PTCA on LAD (n=933, 64.1%), angina (n=370, 25.4%), hypertrophic cardiomyopathy (n=11, 0.8%), hypercholesterolemia (n=38, 2.6%), systemic sclerosis (n=77, 5.3%), others reasons (n=25, 1.7%) ( Table 1 ).
All coronary active medications were not withdrawn before the echocardiographic study, although metilxantine-containing medications were withheld 48 hours before the study. Beverages containing metilxantine substances (coke, tea, coffee etc.) were prohibited for 24 hours before the study. Written informed consent to use medical records for scientific purposes was obtained from all patients. The study was approved by the Ethics Committee of our University Hospital.
| Study protocol
Transthoracic echocardiography and color Doppler CFVR were evaluated using transthoracic Doppler before and after adenosine infusion. Echocardiography was performed with different echo machines (Acuson Sequoia ultrasound unit Siemens, Mountain View, CA, USA; iE33 Philips, Bothell, WA, USA, My-Lab 30 gold Esaote, Florence, Italy) using a broad-band transducer with second harmonic capability. The method has been previously described in detail. Blood pressure and EKG were recorded at rest and every minute during adenosine infusion.
Coronary flow velocity reserve in the LAD was calculated as the ratio of peak diastolic velocity during hyperemia over peak diastolic velocity at rest (for each parameter, the highest 3 were averaged) 10 ( Figure 1 ). 
| Statistics
| RESULTS
| Feasibility and reasons for discontinuing adenosine infusion
Of the consecutive 1455 patients referred to our laboratory, 1429 had a diagnostic noninvasive assessment of CFVR (feasibility 98.2%) including 
| Duration of CFR test and hemodynamic parameters
The mean duration of adenosine infusion was 3.45±2 minutes (range 1-7 minutes). During adenosine infusion, we observed a mild reduction in blood pressure and a moderate increase in heart rate.
Systolic arterial pressure decreased from 139.9±21 to 134.7±21 and diastolic arterial pressure from 81.3±10.6 to 77.7±11.4 (P<.0001 respectively), and only three patients had consistent reduction in systolic blood pressure (systolic blood pressure <80 mm Hg). Heart rate during adenosine increased progressively and significantly from 68.2±12.8 to 86.3±16.3 (P<.0001), with a range during adenosine infusion from 31 to 148 beats per minute.
| Results of coronary flow velocity reserve
The average value of CFVR in the general population was 2.78±0.79. showed significant LAD coronary stenosis (lumen narrowing >70%) and a PTCA was performed, whereas eight (16%) showed angiographically normal coronary artery, and a diagnosis of microvascular angina was made.
Of the other 14 patients with reduced CFVR, 10 had a systemic sclerosis: Seven patients (70%) performed a coronary computed tomography angiography with no evidence of coronary artery stenosis.
Finally, four patients had a diagnosis of hypertrophic cardiomyopathy, and a clinical follow-up program was scheduled.
| Adverse effects of adenosine stress
No major complications were observed during all studies, such as death, myocardial infarction, sustained ventricular arrhythmia or highdegree atrioventricular block or convulsive seizures.
The adverse effects of adenosine infusion were classified as noncardiac effects, cardiac, and arrhythmias, as for other stress tests 18 ( Figure 3 ). The total incidence of side effects of adenosine infusion was 43.7%: The incidence was similar over the years. We found an inverse correlation between age and experience of side effects (r=−. 
| Noncardiac adverse effects
Minor symptoms or adverse noncardiac effects occurred in 548 patients (38.3%). The most frequent symptom reported with regard to adenosine infusion was shortness of breath (n=239, 16.7%). One hundred forty patients (9.9%) suffered atypical chest pain without specific ST-T changes on the EKG. Other effects were flushing (134, 9.4%), headache (95, 6.6%), marked asthenia, and general malaise (80, 5.5%) ( Table 2 ). The majority of noncardiac side effects were well tolerated, and no patient required early suspension of the test before they could reach the maximum vasodilator effect to correctly assess the CFVR. 
| Cardiac symptoms ad arrhythmias
Cardiac symptoms occurred in 35 patients (2.4%). Twenty-two patients (1.5%) manifested typical angina pectoris with ischemic changes on the EKG, but the angina reversed spontaneously with adenosine infusion withdrawal. In only two patients, sublingual nitrates were administered, and none required the intravenous injection of nitrates.
Thirteen patients (0.9%) complained of palpitations, and three patients (0.2%) had symptomatic reduction in systolic blood pressure (systolic blood pressure <80 mm Hg) ( Table 2) 
| DISCUSSION
This study demonstrates, for the first time, the high feasibility and tolerability of noninvasive assessment of CFVR with TTE in a large cohort of women with suspected or known coronary artery disease.
Several methods are now available and well known for measuring CFR.
However, these methods are either invasive or expensive and, consequently, rarely accessible. 8, 9 Transesophageal Doppler echocardiography has been proposed in the past as a method for assessing CFVR by measuring blood flow velocity before and after pharmacologicalinduced vasodilation 19 and most recently cardiac magnetic resonance imaging with adenosine stress, 20, 21 although this test is still not available in most cardiology departments.
The accuracy and reproducibility of this method have been confirmed in a series of patient studies during cardiac catheterization with quantitative coronary angiography and intracoronary Doppler flow wire. 12 In the clinical setting, CFVR is used for the diagnosis of coronary stenosis in the LAD and posterior descending coronary artery [10] [11] [12] 22 and to follow patients who have had a percutaneous coronary angioplasty. 23, 24 Moreover, noninvasive CFVR is useful not only in the evaluation of patients with obstructive coronary artery disease patients, but also to assess different pathologies with functional and/ or anatomic dysfunction of coronary microcirculation. role could be very important in the CAD evaluation in women. Sharaf et al., 28 in the Women's Ischemia Syndrome Evaluation (WISE) study, reported that 30% of women with chest pain undergoing coronary angiography have normal or nonobstructive epicardial coronary arteries, 23% have a mild lesion, and only 15% of patients have a multivessel disease. Obviously, the different pathophysiology strongly influences the accuracy of diagnostic tests commonly used in the study of ischemic heart disease. In fact, these tests are always focused on identifying critical stenosis of epicardial coronary vessels with difficult detection of those patients, mostly women, but at high risk for ischemic disease, who do not have hemodynamically significant coronary stenosis. The WISE group has proposed a flowchart which shows the role of evaluation of microvascular function, 29 measuring the coronary flow reserve, especially since today it can be studied noninvasively with transthoracic echocardiography, [10] [11] [12] [13] [14] [15] [16] [17] [22] [23] [24] [25] [26] [27] and the recent European guidelines 30 for stable coronary artery disease recommend transthoracic Doppler echocardiography of the LAD to assess CFVR in patients with suspected microvascular angina. 
| Feasibility and adverse effects of adenosine stress
Our study examined for the first time, a large series of women scheduled for noninvasive CFVR with intravenous adenosine infusion and evaluated not only feasibility, as other studies did, 25 but also the safety and the adverse effects. Our study confirms the high feasibility (98, 8%) of a noninvasive CFVR study in most of the patients, as well as in those with large body habitus or with an inadequate acoustic window, as previous small studies reported. [10] [11] [12] The feasibility of the examination has grown steadily over the years, with the greater expertise of the operators, and has become extremely important from a clinical standpoint. In this regard, our data show that the test is very rapid. Indeed, the mean time of adenosine infusion was 3.45±2 minutes and, due to adenosine rapid action (peak effect in 55±33 s vs 287±101 with dipyridamole), 33 reserve. [35] [36] [37] Although literature data are promising, the side effects still persist, even with the regadenoson, 38 and the costs are still high. In our study, the incidence of total adverse effects could appear as high (43.7%), but nevertheless much less than in previous studies involving adenosine, 39 and none of these symptoms required the discontinuation of the infusion of adenosine before a diagnostic test. Ventricular and atrial premature beats were the most recurrent arrhythmias during adenosine infusion. In our large series of women, not one manifested life-threatening arrhythmias or myocardial infarction or prolonged myocardial ischemia as reported in some cases in literature. 40 The absence of induced ischemia or severe arrhythmia during adenosine stress in our patients could possibly be related to the fact that we did not discontinue the cardiac therapy (eg, antianginal therapy) for the CFVR assessment, which is a well-known limitation for other ischemia stress tests. 41 Thus, our results show that noninvasive CFVR evaluation is as reliable and safe a test as other pharmacological stress tests, which utilize dobutamine or dipyridamole. 18, 42 In addition, concerning the dipyridamole and dobutamine stress tests, where it is often necessary to administer an antagonist (theophylline and beta-blocker), in none of our patients, was it necessary to infuse an antagonist of adenosine.
| CONCLUSION
Noninvasive assessment of CFVR with TTE is a very feasible method with a very low incidence of adverse events and complications in women with suspected and known coronary artery disease. It can be used and safely performed in the evaluation of atherosclerotic LAD disease and microvascular impairment in women with suspected or known coronary artery disease.
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